MY ACCOUNT | NEWSLETTER |

Canine papillomavirus: status of diagnostic methods and vaccine innovations


Canine Papillomavirus (CPV) is a prevalent viral infection in dogs, characterized by the formation of benign warts or papillomas on the skin and mucous membranes. While most CPV types result in non-malignant growths, certain strains, particularly in immunocompromised dogs (e.g., sick or elderly animals), can lead to malignant transformations.

This highlights the need for early, accurate diagnosis, alongside preventive vaccination, to manage the disease effectively. Diagnostic methods leverage CPV’s unique characteristics, including histopathology with hematoxylin and eosin (H&E) staining for assessing neoplastic tissue growth and cytopathy, molecular techniques like polymerase chain reaction (PCR), rolling circle amplification (RCA), DNA in situ hybridization (ISH), and next-generation sequencing (NGS) for detecting CPV genomic DNA, immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) for identifying viral antigen such as the L1 protein, as well as transmission electron microscopy (TEM) for visualizing viral particles in lesions. These approaches display appreciable sensitivity and specificity and are often utilized in CPV research, though they also have certain intrinsic limitations, such as accessibility, technical complexity.

Advancements in CPV vaccine development, including inactivated, live-attenuated, DNA-based, and recombinant protein-based formulations, show promise in achieving effective protection. However, a commercially available vaccine has yet to be developed. Furthermore, challenges persist in developing convenient, cost-effective diagnostics suitable for diverse clinical applications and in formulating affordable, cross-protective vaccines.

This review emphasizes the importance of continued innovation in CPV diagnostics and vaccine development to mitigate both benign and malignant papillomatosis, enhance disease prevention, and safeguard canine health.


Author: Yuan Feng, Kaixin Wang, Dan Zhou, Youqing Yuan, Yingyi Chen, Jixian Wang, Haojie Sun, Xiaojiu Huang, Xiaoye Peng, Yi Yang, Deyong Duan, Aibing Wang

Source: https://link.springer.com/

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Penn Vet Announces Interim Leadership for the Department of Clinical Sciences and Advanced Medicine, and Ryan Hospital

Like0
Dislike0

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

Like0
Dislike0

Comparison of two host cell range variants of feline immunodeficiency virus

Like0
Dislike0

Canine babesiosis: a perspective on clinical complications, biomarkers, and treatment

Like0
Dislike0

The use of growth promoters in swine nutrition: Problems and perspectives concerning public health and swine production

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top